Direct answer. Spontaneous coronary artery dissection, or SCAD, is an artery-wall problem that can reduce coronary blood flow and cause a heart attack. It can occur without the usual pattern of plaque-related disease. Emergency assessment is essential; once the diagnosis is established, decisions about procedures, medicines and recovery need SCAD-specific specialist judgment.
- SCAD concerns separation or bleeding within a coronary artery wall, rather than simply a cholesterol blockage.
- A heart attack can occur in someone with few conventional cardiovascular risk factors.
- SCAD management can differ from ordinary plaque-related ACS care.
- Selected stable patients may be monitored conservatively; that means clinical care, not home observation of new chest pain.
- The cited specialist papers disclose relevant pharma/device ties and are used as clinical context, not independent efficacy proof.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What differs from plaque disease? | NHLBI heart attack causes | An artery-wall bleed or dissection can obstruct flow; the mechanism changes care decisions. |
| Procedure or conservative management? | ESC SCAD position paper 2018 | Specialist judgment distinguishes stable from high-risk presentations; consensus and observational context are not clean comparative trials. |
| Recovery? | AHA SCAD scientific statement 2018 | Individualized rehabilitation and follow-up questions matter; the financially conflicted statement is not treated as independent outcome proof. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
NHLBI describes SCAD among non-plaque causes of an acute coronary event. Blood collecting within the wall can compress the channel through which blood normally flows. A visible tear is not the only way an artery-wall problem may develop. This is different from a catheter-related injury or a plaque narrowing, even when the acute symptoms are similar. NHLBI heart attack causes.
SCAD is an important diagnostic consideration when the clinical picture suggests a heart attack despite few conventional risk factors. Neither a healthy lifestyle nor young age should be used to dismiss concerning symptoms. The initial priority remains assessment of a possible acute cardiac event. NHLBI heart attack symptoms.
How it works
The compromised artery cannot reliably deliver blood to the affected heart muscle. The acute consequences depend on the territory involved and the severity of impaired flow. A heart attack, rhythm complication or serious pumping problem can develop; a diagnosis of SCAD describes the artery mechanism, not a guaranteed level of severity. NHLBI heart attack causes.
The 2018 ESC position paper distinguishes the artery-wall mechanism from atherosclerotic disease and discusses uncertainty in how the bleeding or separation begins. It also describes associated arterial conditions, including fibromuscular dysplasia. Associations do not establish that every affected person has the same cause. This is attributed specialist context from a materially conflicted source. ESC SCAD position paper 2018.
The evidence-based treatments
The emergency team evaluates ECG, biomarkers and other findings and decides whether coronary assessment is needed. The presence of an artery-wall disorder can change how invasive imaging and procedures are weighed. Diagnostic labels should explain the evidence, rather than simply assume that every infarction came from plaque. NHLBI heart attack diagnosis.
The cited 2018 consensus favours a conservative clinical approach when circumstances permit, while recognizing high-risk situations that may require revascularisation. Conservative care involves specialist observation and treatment; it is not advice to remain at home with a possible heart attack. These are consensus distinctions, not a financially independent trial estimate of superiority. ESC SCAD position paper 2018.
The same paper notes that a statin needs an indication separate from the mere presence of SCAD. Other medicines can have purposes related to heart function, symptoms, blood pressure or a procedure. Do not stop prescribed therapy from this statement: the clinician must establish whether such an indication applies. ESC SCAD position paper 2018.
The AHA statement describes uncertainty around several treatment and follow-up questions. Ask which parts of the plan address the confirmed SCAD mechanism, which address consequences such as impaired heart function, and which address another condition. A clear explanation prevents a standard “heart attack” medicine list from being mistaken for evidence that all causes are identical. AHA SCAD scientific statement 2018.
Supplement and lifestyle evidence
The AHA statement supports a tailored rehabilitation and activity discussion after SCAD, rather than an extreme exercise rule copied from another patient. General post-infarction recovery resources can help explain rehabilitation services, but the SCAD team should adapt the plan to the artery-wall diagnosis and clinical findings. AHA SCAD scientific statement 2018; NHLBI heart attack recovery.
No supplement is established here as a treatment for spontaneous coronary artery dissection. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care identifies the artery-wall mechanism, states why a procedure or monitored strategy was chosen and explains the purpose of each prescription. A recurrent-event percentage from a selected registry should not be turned into a personal forecast or a supplement prevention claim.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
New persistent chest discomfort, severe breathlessness, sweating, nausea, faintness or collapse need the local emergency service. An earlier SCAD diagnosis does not establish the cause of the next episode. Do not drive yourself or delay to compare symptoms with a previous event. NHLBI heart attack symptoms; NHS heart attack.
Procedures and antithrombotic treatment can have different trade-offs when the underlying problem involves the arterial wall. A care plan should explain risks without implying that the diagnosis makes every intervention unsafe. The team weighs the actual presentation, stability and other indications. The relevant consensus sources have industry ties disclosed below. AHA SCAD scientific statement 2018.
Important interactions
Antithrombotic decisions, a recent stent, other reasons for anticoagulation and bleeding history need reconciliation by the treating team. Do not infer from an artery-wall bleed that a prescribed medicine is necessarily wrong; stopping it can also create risk. Tell the clinician about hormonal therapies and all other products. AHA SCAD scientific statement 2018.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
People with concerning acute symptoms should avoid assuming that a normal home pulse, fitness level or low cholesterol excludes a coronary event. A prior anxiety diagnosis also cannot establish the cause of new symptoms. NHLBI heart attack symptoms.
Pregnancy, future pregnancy planning, hormonal medicines and possible associated arterial disease deserve specialist discussion after SCAD. The 2018 AHA statement identifies these as individualized questions with evidence gaps. A universal ban or a reassuring internet promise does not substitute for that assessment. AHA SCAD scientific statement 2018.
Clinician-led use and follow-up
Ask what remains uncertain, whether assessment for associated arterial disease is appropriate, how heart function will be reviewed and how activity will be rebuilt. Bring the discharge summary to subsequent appointments so that the SCAD diagnosis and procedure details inform future care. NHLBI heart attack recovery.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Models of artery-wall fragility, connective tissue and hormonal effects can generate hypotheses about SCAD. They do not establish an individual cause, a preventive supplement or a safe exercise threshold. No laboratory finding or uncontrolled association is used here as independent proof of treatment efficacy.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 9 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
SCAD has financial interests in catheter imaging, coronary devices, antithrombotic medicines and specialist research. Both original 2018 consensus papers were opened and their funding and author disclosures checked. Relevant pharmaceutical/device ties lead to grade C contextual use; those papers do not establish this guide’s independent efficacy verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI heart attack causes | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public SCAD mechanism and heart-attack causes. |
| NHLBI heart attack symptoms | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Emergency warning signs. |
| NHLBI heart attack diagnosis | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Initial acute cardiac assessment. |
| ESC SCAD position paper 2018 | Original paper names British Heart Foundation, NIHR RD-TRC and Leicester NIHR Biomedical Research Centre support to D. Adlam. Authors disclose AstraZeneca and St Jude/Abbott grants and relevant pharma fees, including H. Bueno’s declarations during the work. ESC also reports life-science and medtech income. | Authors in UK, Spain, Netherlands and Belgium; ESC headquarters France. Public/charitable UK support and multinational pharma/device ties; manufacturing origin not established. | Tier 2 for consensus with material relevant author and society industry ties; excluded from independent efficacy verdict. | C. Detailed clinical expertise and disclosed conflicts support contextual use; observational selection, 2018 publication and commercially relevant relationships remain. Role: Dated 2018 specialist consensus; material commercial ties; contextual use only. |
| AHA SCAD scientific statement 2018 | Original statement names the Ann Fensterwald Eisenstein family’s figure support. Disclosure table reports J. Saw’s Abbott Vascular SCAD research support and Abbott/Boston Scientific consulting, alongside other author commercial ties. Public and charitable research support is also listed; a complete society donor chain was not traced. | US AHA, Dallas; writing group includes US, Canadian and UK institutions. Commercial supporter manufacturing origin not established. | Tier 2 materially relevant industry relationships in consensus; excluded from independent efficacy verdict. | C. Explicit disclosure table and specialist review aid contextual accuracy; 2018 evidence, observational studies and device-related ties limit independent outcome use. Role: Dated 2018 specialist statement and disclosures; contextual use only. |
| NHLBI heart attack recovery | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: General post-infarction recovery context. |
| NHS heart attack | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: UK acute recognition and hospital context. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
Frequently asked questions
Is SCAD another name for cholesterol plaque?
No. It concerns an artery-wall problem that can compromise flow. NHLBI heart attack causes.
Does conservative management mean no medical care?
No. It is a specialist clinical strategy for selected circumstances. ESC SCAD position paper 2018.
Are all usual heart-attack medicines automatically required?
The reason for each medicine needs review against SCAD, its consequences and other indications.
Can recurrent discomfort simply be ignored?
No. A previous diagnosis does not safely determine the cause of a new concerning episode. NHLBI heart attack symptoms.
Sources and funding notes
- NHLBI heart attack causes — Public SCAD mechanism and heart-attack causes.
- NHLBI heart attack symptoms — Emergency warning signs.
- NHLBI heart attack diagnosis — Initial acute cardiac assessment.
- ESC SCAD position paper 2018 — Dated 2018 specialist consensus; material commercial ties; contextual use only.
- AHA SCAD scientific statement 2018 — Dated 2018 specialist statement and disclosures; contextual use only.
- NHLBI heart attack recovery — General post-infarction recovery context.
- NHS heart attack — UK acute recognition and hospital context.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. Where cited, the 2026 definition was read through the web tool; its author supplement was inaccessible and remains an explicit gap. Where cited, the 2018 SCAD papers were read in original full versions, including funding and disclosure tables. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.